Last reviewed · How we verify
Tocilizumab plus methotrexate
Tocilizumab plus methotrexate is a IL-6 receptor antagonist + DMARD combination Small molecule drug developed by SURPRISE Study Group. It is currently FDA-approved for Rheumatoid arthritis (moderate to severe, active disease). Also known as: Actemra, Methotrexate.
Tocilizumab blocks IL-6 receptor signaling to reduce inflammation, while methotrexate inhibits dihydrofolate reductase to suppress immune cell proliferation.
Tocilizumab is not mentioned in the provided facts, so it cannot be included in the summary. However, based on the information, methotrexate (MTX) is an intervention studied in clinical trials for conditions such as Rheumatoid Arthritis.
At a glance
| Generic name | Tocilizumab plus methotrexate |
|---|---|
| Also known as | Actemra, Methotrexate |
| Sponsor | SURPRISE Study Group |
| Drug class | IL-6 receptor antagonist + DMARD combination |
| Target | IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tocilizumab is a monoclonal antibody that binds to IL-6 receptors (both membrane-bound and soluble forms), blocking the pro-inflammatory cytokine IL-6 from activating immune cells. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, reducing nucleotide synthesis and thereby suppressing T-cell and B-cell proliferation. Together, this combination targets inflammation through complementary mechanisms.
Approved indications
- Rheumatoid arthritis (moderate to severe, active disease)
Common side effects
- Infection (including serious infections)
- Elevated liver enzymes
- Neutropenia
- Gastrointestinal disturbances
- Headache
Key clinical trials
- An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis (PHASE2)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (PHASE4)
- Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis (PHASE3)
- Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease (PHASE3)
- A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tocilizumab plus methotrexate CI brief — competitive landscape report
- Tocilizumab plus methotrexate updates RSS · CI watch RSS
- SURPRISE Study Group portfolio CI
Frequently asked questions about Tocilizumab plus methotrexate
What is Tocilizumab plus methotrexate?
How does Tocilizumab plus methotrexate work?
What is Tocilizumab plus methotrexate used for?
Who makes Tocilizumab plus methotrexate?
Is Tocilizumab plus methotrexate also known as anything else?
What drug class is Tocilizumab plus methotrexate in?
What development phase is Tocilizumab plus methotrexate in?
What are the side effects of Tocilizumab plus methotrexate?
What does Tocilizumab plus methotrexate target?
Related
- Drug class: All IL-6 receptor antagonist + DMARD combination drugs
- Target: All drugs targeting IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate)
- Manufacturer: SURPRISE Study Group — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis (moderate to severe, active disease)
- Also known as: Actemra, Methotrexate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing